Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)

NCT01244217 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhinitis Perennial

Interventions

DRUG: fexofenadine/Allegra (M016455)

Sponsor

Sanofi